Everest Medicines Limited convened an extraordinary general meeting (EGM) on 16 November 2026 via an online platform, at which shareholders voted on a single ordinary resolution to approve, confirm and ratify the company’s Strategic Cooperation Framework Agreement, including annual caps for the financial years ending 31 December 2026, 2027 and 2028, and all related transactions.
The resolution passed with 21.11 million votes in favour (66.40%) and 10.68 million votes against (33.60%). Because a simple majority was achieved, the proposal was duly adopted.
Key participation and voting details: • Total shares in issue as at the record date: 354.64 million. • Shares qualified to vote: 354.64 million; no treasury shares were held. • Trustees holding 0.97 million unvested scheme shares abstained from voting in compliance with Listing Rule 17.05A. • Shareholders linked to Mr. Wei Fu and CBC Group, together holding 89.42 million shares, abstained from voting on the resolution, as required under the Listing Rules. • No other shareholders were required to abstain, and no votes were cast under Rule 13.40 of the Listing Rules.
Computershare Hong Kong Investor Services Limited acted as scrutineer for the poll. The meeting was chaired by Chairman and Executive Director Mr. Yifang Wu, with all board members in attendance.
The EGM outcome formalises shareholder backing for Everest Medicines’ planned strategic cooperation, setting defined annual transaction caps through 2028.
Comments